AI in the Real World · AI Spotlight
Agentic AI Is Quietly Reshaping Healthcare. Here Is How.
Life sciences companies are betting their entire commercial strategy on AI agents that do not just answer questions. They autonomously execute the plan.
Hey there, Welcome back 👋
Most AI tools still wait for you to ask them something.
You type a prompt. It answers. You type another prompt. It answers again. That loop works fine for writing emails or summarising documents. But it breaks down completely when the task requires pulling data from five different systems, making a decision, acting on it, and then measuring the outcome, all without a human holding its hand at every step.
That is the exact problem pharmaceutical companies face right now. And it is why agentic AI, AI that does not just answer prompts but autonomously executes complex multi-step tasks, is becoming one of the biggest bets in healthcare marketing.
The numbers behind that bet are significant. According to a Capgemini Invent report, AI agents could generate up to $450 billion in economic value through revenue uplift and cost savings globally by 2028. And 69% of executives are already planning to deploy agents in marketing processes by the end of this year.
Here is what is actually happening and why it matters beyond pharma.
* * *
|
The Opportunity in Numbers
|
* * *
|
The Fragmented Intelligence Problem |
Picture this scenario. A doctor attends a medical conference. A competitor showcases promising new drug results. The doctor reads the published research, shifts their prescriptions to the rival product, all within a single quarter.
Meanwhile, the pharmaceutical sales rep who has a relationship with that doctor walks into their next meeting completely blind. The conference attendance is in one database. The prescribing shift is in another. The published research interest is in a third. None of those systems talk to each other. The rep has no idea what happened.
This is not a niche problem. It is the default state of pharmaceutical marketing. Legacy IT infrastructure keeps critical intelligence trapped in silos. CRM systems, events databases, and claims data all sitting in separate systems that nobody has connected.
|
The Core Problem The solution is not connecting the systems. That takes years and massive IT budgets. The solution is deploying agentic AI that can autonomously query across all of them simultaneously and then act on what it finds. |
Instead of a data engineer spending weeks building a new pipeline, an AI agent could autonomously answer a business question like: "Identify oncologists in the Northwest who have a 20% lower prescription volume but attended our last medical congress." No new pipeline. No weeks of work. Just the answer, in seconds, ready to act on.
* * *
|
From Answering Questions to Executing Plans |
The shift being described here is not incremental. It is a fundamental change in what AI is actually for.
Conversational AI responds to queries. You ask, it answers. Agentic AI independently executes multi-step tasks. You define an objective, it figures out how to achieve it, takes the necessary actions across multiple systems, and reports back with results, not just information.
In pharmaceutical marketing, this looks like a sales rep asking an agent: "Create a detailed intelligence brief on my HCP before my visit tomorrow." The agent does not return a list of links. It compiles a complete briefing document:
|
What the Agent Compiles Autonomously
|
|
"Agentic AI is about graduating from 'answer my prompt' to 'autonomously execute my task.' The sales rep stops asking questions and starts coordinating small teams of specialised agents." Briggs Davidson, Capgemini Invent |
* * *
|
The 3 Things AI-Ready Data Unlocks |
None of this works without what Capgemini calls AI-ready data, standardised, accessible, complete, and trustworthy information flowing across systems. When that foundation exists, three specific capabilities become possible:
|
Capability 01 Faster Decision Making Predictive analytics that provide near real-time alerts on what is about to happen, not what happened last month. Sales reps act before the prescribing shift happens, not after they notice it in a quarterly report. |
|
Capability 02 Personalisation at Scale Delivering customised experiences to thousands of healthcare professionals simultaneously with small human teams. Not segmented campaigns. Actual individual personalisation, the kind that previously required one human per relationship. |
|
Capability 03 True Marketing ROI Moving beyond monthly historical reports to understanding which marketing activities are actively driving prescriptions right now. Not which activities drove prescriptions ninety days ago. The difference between reactive and proactive commercial strategy. |
* * *
|
What the Report Does Not Answer |
The $450 billion figure is compelling. The vision of autonomous agents coordinating across CRM, events, and claims systems is technically credible. But there are real questions the report leaves unaddressed.
|
The Critical Gaps Regulatory complexity. Autonomous systems querying claims databases containing prescriber behaviour run directly into HIPAA's minimum necessary standard. Who is accountable when an AI agent accesses data it technically should not have touched? No real client metrics. The report references aspirational projections, not documented outcomes from actual implementations. The $450 billion number is a ceiling, not a floor. Global variation. Deployment will vary significantly across regulatory environments. A use case that works in the US may be completely off-limits in the EU under GDPR. The report acknowledges this without addressing it. |
These are not reasons to dismiss agentic AI in healthcare. They are reasons to watch this space carefully, because the companies that figure out the compliance layer first will have an enormous advantage over those that move fast and break things in a highly regulated industry.
* * *
The Bigger Picture
Healthcare is one of the highest-stakes environments for agentic AI precisely because the data is sensitive, the regulation is real, and the consequences of a bad autonomous decision are not just financial.
But the operational problem it is solving, fragmented data, missed signals, reps walking into meetings without context, is not unique to pharma. It is the default state of most large organisations. The playbook being developed in life sciences marketing will eventually land in financial services, retail, logistics, and every other sector where sales relationships matter and data is siloed.
The question is not whether agentic AI reaches these industries. It is which companies are ready with AI-ready data when it arrives, and which ones are still arguing about whose budget owns the data pipeline.
|
"The full value of agentic AI only materialises with AI-ready data, trustworthy deployment, and workflow redesign. Miss any one of the three and the $450 billion stays on paper." |
Do you think agentic AI will actually hit that $450 billion mark by 2028, or will compliance slow it down? Hit reply. I read every response.
Until Next Time,
AI Spotlight
The no-fluff AI newsletter. Real tools, real trends, real impact.